Katherine Donegan

1.6k total citations · 1 hit paper
20 papers, 1.1k citations indexed

About

Katherine Donegan is a scholar working on Epidemiology, Infectious Diseases and Health. According to data from OpenAlex, Katherine Donegan has authored 20 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Epidemiology, 6 papers in Infectious Diseases and 4 papers in Health. Recurrent topics in Katherine Donegan's work include HIV/AIDS drug development and treatment (4 papers), Vaccine Coverage and Hesitancy (4 papers) and Influenza Virus Research Studies (3 papers). Katherine Donegan is often cited by papers focused on HIV/AIDS drug development and treatment (4 papers), Vaccine Coverage and Hesitancy (4 papers) and Influenza Virus Research Studies (3 papers). Katherine Donegan collaborates with scholars based in United Kingdom, Netherlands and United States. Katherine Donegan's co-authors include P J Bryan, B. King, Elizabeth Miller, Helen Campbell, Mary Ramsay, Sonia Ribeiro, Edna Kara, Gayatri Amirthalingam, Norman K. Fry and Nick Andrews and has published in prestigious journals such as The Lancet, BMJ and SLEEP.

In The Last Decade

Katherine Donegan

18 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effectiveness of maternal pertussis vaccination in England: an observational study

2014 529 citations Gayatri Amirthalingam, Nick Andrews et al. The Lancet profile →

Peers

Countries citing papers authored by Katherine Donegan

Since Specialization

Citations

This map shows the geographic impact of Katherine Donegan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katherine Donegan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katherine Donegan more than expected).

Fields of papers citing papers by Katherine Donegan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katherine Donegan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katherine Donegan. The network helps show where Katherine Donegan may publish in the future.

Co-authorship network of co-authors of Katherine Donegan

This figure shows the co-authorship network connecting the top 25 collaborators of Katherine Donegan. A scholar is included among the top collaborators of Katherine Donegan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katherine Donegan. Katherine Donegan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Regulatory Perspective on a UK Federated Data Network for Medicines and Medical Devices: Lessons from a ‘Study-A-Thon’ 2025 ·Therapeutic Innovation & Regulatory Science ·Helen Booth, John Connelly, Daniel Dedman, Katherine Donegan, Alison Cave	0
2	Implementation and Results of Active Vaccine Safety Monitoring During the COVID-19 Pandemic in the UK: A Regulatory Perspective 2025 ·Drug Safety ·Jenny Wong, Katherine Donegan, (unknown), (unknown), Alison Cave, Phil Tregunno	0
3	Sharing Is Caring? International Society for Pharmacoepidemiology Review and Recommendations for Sharing Programming Code 2024 ·Pharmacoepidemiology and Drug Safety ·John Tazare, Shirley Wang, Rosa Gini, Daniel Prieto‐Alhambra, Peter Arlett, (unknown), Caroline E Morton, John Logie, Jennifer Popovic, Katherine Donegan, Sebastian Schneeweiß, Ian Douglas, Anna Schultze	2
4	A European multicentre drug utilisation study of the impact of regulatory measures on prescribing of codeine for pain in children 2019 ·Pharmacoepidemiology and Drug Safety ·Karin Hedenmalm, Kevin Blake, Katherine Donegan, M. Maciá, Miguel Gil, Julie Williams, Dolores Montero, Gianmario Candore, Daniel R. Morales, Xavier Kurz, Peter Arlett	14
5	How Clinical Practice Research Datalink data are used to support pharmacovigilance 2019 ·Therapeutic Advances in Drug Safety ·Rebecca Ghosh, (unknown), (unknown), Katherine Donegan, Puja Myles, Rachael Williams	28
6	Benefit–Risk Monitoring of Vaccines Using an Interactive Dashboard: A Methodological Proposal from the ADVANCE Project 2018 ·Drug Safety ·Kaatje Bollaerts, Tom De Smedt, Katherine Donegan, Lina Titievsky, Vincent Bauchau	12
7	Safety of multicomponent meningococcal group B vaccine (4CMenB) in routine infant immunisation in the UK: a prospective surveillance study 2018 ·The Lancet Child & Adolescent Health ·(unknown), Suzie Seabroke, Jenny Wong, Katherine Donegan, Elizabeth Webb, (unknown), Caroline Vipond, Ian M. Feavers	46
8	Exploring the Potential Routine Use of Electronic Healthcare Record Data to Strengthen Early Signal Assessment in UK Medicines Regulation: Proof-of-Concept Study 2018 ·Drug Safety ·Katherine Donegan, Rebecca Owen, (unknown), (unknown), (unknown), Phil Tregunno	4
9	Trends in diagnosis and treatment for people with dementia in the UK from 2005 to 2015: a longitudinal retrospective cohort study 2017 ·The Lancet Public Health ·Katherine Donegan, Nick C. Fox, Nick Black, Gill Livingston, Sube Banerjee, Alistair Burns	102
10	The impact of regulatory action on the co‐prescribing of renin–angiotensin system blockers in UK primary care 2017 ·Pharmacoepidemiology and Drug Safety ·(unknown), Katherine Donegan	9
11	Risk of Narcolepsy after AS03 Adjuvanted Pandemic A/H1N1 2009 Influenza Vaccine in Adults: A Case-Coverage Study in England 2016 ·SLEEP ·Julia Stowe, (unknown), Christopher Kosky, Gary Dennis, Sofia Eriksson, Andrew P. Hall, Guy Leschziner, Paul Reading, John M. Shneerson, Katherine Donegan, Elizabeth Miller	38
12	Patterns of anti-diabetic medication use in patients with type 2 diabetes mellitus in England and Wales 2016 ·Pharmacoepidemiology and Drug Safety ·(unknown), A. G. Thomson, (unknown), Katherine Donegan	16
13	Effectiveness of maternal pertussis vaccination in England: an observational study breakdown → 2014 ·The Lancet ·Gayatri Amirthalingam, Nick Andrews, Helen Campbell, Sonia Ribeiro, Edna Kara, Katherine Donegan, Norman K. Fry, Elizabeth Miller, Mary Ramsay	529
14	Incidence of Pneumococcal and Varicella Disease in HIV-infected Children and Adolescents in the United Kingdom and Ireland, 1996–2011 2014 ·The Pediatric Infectious Disease Journal ·Helen Payne, Ali Judd, Katherine Donegan, Ifeanyichukwu Okike, Shamez Ladhani, Katja Doerholt, Paul T. Heath	4
15	Safety of pertussis vaccination in pregnant women in UK: observational study 2014 ·BMJ ·Katherine Donegan, B. King, P J Bryan	202
16	Bivalent human papillomavirus vaccine and the risk of fatigue syndromes in girls in the UK 2013 ·Vaccine ·Katherine Donegan, (unknown), (unknown), Suzie Seabroke, (unknown), (unknown)	51
17	Lopinavir Dosing in HIV-infected Children in the United Kingdom and Ireland 2012 ·The Pediatric Infectious Disease Journal ·Katherine Donegan, Katja Doerholt, Ali Judd, Hermione Lyall, Esse Menson, Karina Butler, P Tookey, Andrew Riordan, Delane Shingadia, Gareth Tudor‐Williams, Diana M. Gibb, A. Sarah Walker	12
18	Mean Corpuscular Volume as a Marker for Adherence to Zidovudine-Containing Therapy in HIV-Infected Adults 2012 ·The Open AIDS Journal ·Joseph Mugisha, Katherine Donegan, Sarah Fidler, Gita Ramjee, Andrew Hodson, David Dunn, Kholoud Porter, Pontiano Kaleebu	4
19	The Prevalence of Darunavir-Associated Mutations in HIV-1-Infected Children in the Uk 2012 ·Antiviral Therapy ·Katherine Donegan, A Sarah Walker, David Dunn, Ali Judd, Deenan Pillay, Esse Menson, Hermione Lyall, (unknown), Diana M. Gibb	1
20	The Prevalence of Darunavir-Associated Mutations in HIV-1-Infected Children in the Uk 2011 ·Antiviral Therapy ·Katherine Donegan, A Sarah Walker, David Dunn, Ali Judd, Deenan Pillay, Esse Menson, Hermione Lyall, (unknown), Diana M. Gibb	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact